The elimination of the human immunodeficiency virus inside its central nervous system (CNS) sanctuary is affected by variable antiretroviral therapy (ART) penetrance across the blood-brain barrier (BBB), complex dosing regimens, costs, toxicities, and limitations in biodistribution and pharmacokinetic drug patterns. Despite advances in ART NeuroAIDS morbidities continue. A principal issue obstacle in achieving maximal clinical responses is in maintaining ART drug levels in disease affected brain subregions. To address this issue, we developed nanformulations of antiretroviral drugs and delivered them inside circulating blood-borne monocyte-macrophages. The means to improve distribution of ART across the BBB included testing of nanoparticle (NP) drug formulation(s) for entry and secretion into and from bone marrow-derived macrophages (BMM) and monocytederived macrophages. Here, viral protease inhibitor(s) are being packaged into phospholipids coated NP. Cytotoxicity, anti-retroviral efficacy, mobility, and the functional consequences of macrophage carriage of the drug-laden particles are measured. Second, pharmacokinetics (uptake, release, plasma and tissue distribution) of the formulations is being investigated using BMM as a drug delivery system in mice. Third, optimal ways to enhance uptake of NP formulations are being developed. In this way, the abilities of drug to bypass the reticuloendothelial system and cross the BBB can be determined. High performance liquid chromatography analyses are used to measure drug levels in spleen, lymph nodes, liver and brain in NP-treated mice and provide confirmation of drug tissue penetrance. These tests are used in tandem with histology and imaging assays. Lastly, the NP are tested for anti-retroviral efficacy in humanized mouse models of human HIV-1 CNS disease. All together, our works explore the means to enhance therapeutic efficacy and BBB migration of ART so that they can be translated for human use to improve disease outcomes in NeuroAIDS.
The elimination of the human immunodeficiency virus inside its central nervous system (CNS) sanctuary is affected by variable antiretroviral therapy (ART) penetrance across the blood-brain barrier (BBB), complex dosing regimens, costs, toxicities, and limitations in biodistribution and pharmacokinetic drug patterns. Despite advances in ART NeuroAIDS morbidities continue. A principal issue obstacle in achieving maximal clinical responses is in maintaining ART drug levels in disease affected brain subregions. To address this issue, we developed nanformulations of antiretroviral drugs and delivered them inside circulating blood-borne monocyte-macrophages. The means to improve distribution of ART across the BBB included testing of nanoparticle (NP) drug formulation(s) for entry and secretion into and from bone marrow-derived macrophages (BMM) and monocytederived macrophages. Here, viral protease inhibitor(s) are being packaged into phospholipids coated NP. Cytotoxicity, anti-retroviral efficacy, mobility, and the functional consequences of macrophage carriage of the drug-laden particles are measured. Second, pharmacokinetics (uptake, release, plasma and tissue distribution) of the formulations is being investigated using BMM as a drug delivery system in mice. Third, optimal ways to enhance uptake of NP formulations are being developed. In this way, the abilities of drug to bypass the reticuloendothelial system and cross the BBB can be determined. High performance liquid chromatography analyses are used to measure drug levels in spleen, lymph nodes, liver and brain in NP-treated mice and provide confirmation of drug tissue penetrance. These tests are used in tandem with histology and imaging assays. Lastly, the NP are tested for anti-retroviral efficacy in humanized mouse models of human HIV-1 CNS disease. All together, our works explore the means to enhance therapeutic efficacy and BBB migration of ART so that they can be translated for human use to improve disease outcomes in NeuroAIDS. Although efficacious treatment greatly improves both the quality of life and overall lifespan in HIV infected individuals, CNS complications continue to affect those with HIV. HIV infects the brain early and persists. Using the SIV/rhesus model, we have assessed the functional, molecular, and immune consequences of chronic infection of the CNS. Experimental interventions, such as non-CNS penetrating antiviral therapy, and CNS immune cell manipulations, have allowed the assessment of peripheral and CNS components of the response to chronic infection in the primate brain, and their contribution to CNS pathophysiology.
S.2 Multifaceted response to SIV in the brain

S.3 Bioimaging and CNS responses to HIV-1 infection Linda Chang and Thomas Ernst John A. Burns School of Medicine, Univeristy of Hawaii at Manoa, The Queen's Medical Center
Despite treatment with potent antiretroviral medications and the significant decline in mortality and opportunistic brain diseases in patients with HIV, HIVassociated cognitive disorder remains a common and persistent morbidity for these individuals. With the longer survival and aging population of HIV patients, cognitive deficits in this patient population may be even more prevalent and may impact their quality of life further. Biomarkers that can reliably measure the brain changes associated with the infection is needed to assess the severity of brain injury, design rational therapy, evaluate treatment effects, and improve the quality of life of individuals living with HIV. A variety of in vivo structural and functional neuroimaging techniques, including magnetic resonance imaging (MRI), MR spectroscopy (MRS), diffusion tensor imaging (DTI), functional MRI (fMRI) and positron emission tomography (PET), can assess brain injury or inflammatory responses associated with HIV. Many of these measures can even detect brain injury during the neuroasymptomatic stages. In addition, quantitative 8th International Symposium on NeuroVirology 4 Oral Presentations measurements with these techniques may serve as surrogate markers to monitor treatment effects.
DTI can measure brain water motion and thus provide quantitative assessment of the inflammatory changes in the brain. Correlation of DTI or MRS with other plasma or CSF markers, such as inflammatory cytokines or chemokines, or clinical assessments with neuropsychological tests, may further validate and provide confirmatory information regarding the effects of HIV infection in the brain. Evaluating inflammatory responses in the brain with DTI may be a sensitive measure to monitor the treatment effects. Findings from some of the neuroimaging studies, such as measures of dopaminergic function with PET, also provide insights into the pathophysiological mechanisms of HIV-associated brain injury and might lead to new therapeutic approaches.
S.4 STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier
Anathbandhu Chaudhuri, Yuri Persidsky, Georgette D Kanmogne
University of Nebraska Medical Center
The relationship between neuroinflammatory signaling pathways, the blood-brain barrier (BBB) and progressive HIV-1 infection as they affect the development of cognitive and motor abnormalities is poorly understood. One possibility to link each of these is through the signal transducers and activators of transcription (STAT) pathways as they respond to pro-inflammatory and regulatory factors, and could affect neuroinflammatory responses from virus infected brain cells. Our previous works demonstrated that HIV-1 activate pro-inflammatory and interferon alpha-inducible genes in human brain microvascular endothelial cells (HBMEC) and that these genes were linked to the janus kinase (JAK)/STAT pathway. We now demonstrate that HIV-1 and HIV-1-infected monocyte-derived macrophages activate STAT1 and induce HBMEC IL-6 expression. The STAT1 inhibitor, fludarabine, blocked HIV-1-induced IL-6 production, blocked HIV-1 and IL-6-induced monocyte migration across in vitro BBB models. Enhanced expression and activation of STAT1 and decreased claudin-5 was observed in microvessels acquired from autopsy brains of patients with HIV-1-associated dementia. These data strongly support the notion that STAT1 plays an integral role in HIV-1-induced BBB damage and is relevant to viral neuropathogenesis. Inhibition of STAT1 activation could provide a unique therapeutic strategy to prevent HIV-1-induced BBB compromise and as such improve clinical outcomes.
Syphilis and HIV can be considered to be co-pathogens for several reasons. Syphilis increases the chance of acquiring or transmitting HIV. During episodes of active syphilis in people infected with HIV, CD4 cell count declines and plasma viral load increases. Thus, HIVinfected individuals with syphilis may be more infectious and even more likely to transmit HIV. Worldwide, the epidemiology of syphilis and HIV support their intimate connection. The WHO estimates that 12 million people acquire syphilis every year, and two-thirds of these individuals reside in sub-Saharan Africa. In Africa, the proportion of individuals with syphilis is 2-3 times higher in those who are HIVinfected compared to HIV-uninfected. Similarly, in the US in 2002, compared to all patients with primary and secondary syphilis, rates of primary and secondary syphilis were 80 times higher in patients who were also HIV-infected. One study estimated that in the US in 1996, syphilis accounted for 1000 new cases of HIV.
HIV-infected individuals may have suboptimal responses to treatment of early syphilis and to treatment of neurosyphilis. Neurorelapse, meaning development of early neurosyphilis after appropriate treatment of early syphilis, is more common in HIV-infected than HIV-uninfected individuals. After neurosyphilis treatment, CSF-VDRL is less likely to normalize in HIVinfected compared to HIV-uninfected individuals, particularly when the CD4 count is <200/ul. Preliminarily findings show that HIV-infected persons who are taking antiretrovirals at the time of neurosyphilis treatment have faster and more complete normalization of CSF measures. Taken together, these findings suggest that an intact immune response is integral to success of treatment for any form of syphilis, even when antibiotics are given.
The appreciation that syphilis and HIV are copathogens offers opportunities to improve public and individual health. It highlights the importance of the host immune response in determining the neurological outcome of syphilis infection and suggests directions for future research.
S.7
Level of HIV-1 DNA in peripheral blood mononuclear cells (PBMCs) increases with severity of neurocognitive dysfunction Bruce Shiramizu, Cecilia Shikuma, Sody Munsaka, Victor Valcour Background. The urokinase plasminogen activator (uPA) system may be involved in the pathogenesis of AIDS dementia complex (ADC) through interaction with HIV-1 and subsequent dysregulation of uPA system functions-extracellular proteolysis and chemotaxis. The aim was to investigate this hypothesis through measurement of CSF and plasma level of uPA molecules and comparison with levels of other HIV-1, immune activation and neuronal markers.
Study
Design:
Cross-sectional study of antiretroviral-untreated patients, including patients with neurologically asymptomatic HIV infection and no AIDS (n = 19); neurologically asymptomatic HIV infection and AIDS (n = 18); ADC (n = 17); and HIV-negative healthy controls (n = 16). CSF and plasma were assessed for uPA system molecules (suPAR, uPA, PAI-1, tPA); immune activation markers (CSF cells and protein, neopterin and the following cytokines and chemokines, measured by the Luminex technology-Bio-Plex, Bio-Rad Laboratories, Inc.: IL-1σ , IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, basic FGF, eotaxin, G-CSF, GM-CSF, IFN-τ ;, IP-10, MCP-1, MIP-1 , MIP-1σ , PDGF-BB, RANTES, TNF-, VEGF); and neuron-associated markers (NFL, t-tau, p-tau, Aσ 1-42, -sAPP and σ -sAPP).
Results. ADC patients had significantly higher CSF and plasma levels of suPAR compared to each of the other groups (p < 0.0001 for all), slightly higher levels of uPA, and no different levels of PAI-1 or tPA. As expected, ADC patients had the highest CSF levels of HIV-1 RNA and MCP-1 and also showed CSF levels of IL-6, MIP-1 ; and MIP-1σ ; significantly higher than in each of the other groups. In the whole group of HIV-infected patients, CSF suPAR correlated strongly (Spearman r coefficient ≥0.50 or <−0.50) with CSF and plasma uPA, and with CSF HIV-1 RNA, MIP-1 , MIP-1σ , neopterin, NFL and tau (direct correlation); and with blood CD4 cells and CSF -sAPP and σ ;-sAPP (inverse correlation).
Conclusions. These findings strongly support the role of the uPA system in the pathogenesis of ADC. The relatively low CSF levels of uPA and the unaltered CSF levels of PAI-1 and tPA do not argue in favor of proteolysis dysfunction as prevalent mechanism. The observation that increased CSF suPAR occurred in parallel with increased levels of HIV-1 and other cytokines and chemokines, seems to support a mechanism by which suPAR would promote migration of inflammatory cells into the CNS and further enhance viral replication. In addition, the strong association between CSF suPAR and neuronal markers suggests that suPAR might also exert direct effects on neuronal cells.
S.9
Oxidative stress markers may serve as a biomarker for the progression of HIV-associated cognitive impairment in women Background: Prevalence of HIV-associated cognitive impairment is increasing as patients treated with antiretroviral treatment (ART) live longer. To date a biomarker(s) to identify HIV-infected patients at risk of developing cognitive impairment is lacking. Markers of CSF oxidative stress may identify HIVinfected patients at risk of developing cognitive impairment and may have a role in the progression of the disease.
Methods: CSF from 62 women followed at the Longitudinal HIV-infected women cohort were evaluated. The Memorial Sloan Kettering Scale (MSK) was used to categorize cognitive function into normal (MSK = 0, n = 8), mild impairment (MSK = 0.5, n = 29), and dementia (MSK ≥ 1, n = 21). Protein carbonyls (PC) were determined by Slot-blot and Western-blot in 47 CSF samples and 4-hydroxynonenal (4-HNE) and sphingomyelin by ESI-MS/MS in 37 CSF samples. Predictive value was based on changes of cognitive status after 6 months and a Kaplan Meyer survival analysis.
Results: At baseline there was a difference in protein carbonyls (p = .048) with post-hoc testing showing that women with mild impairment (MSK = 0.5) presented elevated CSF PC versus women with normal cognition or dementia (MSK = 0 or MSK ≥ 1) (p = .015). In the predictive analysis at 6 months follow up, there weren't any differences. From 20 women who presented at baseline with normal cognition (n = 10) or mild impairment (n = 10) a Kaplan Meyer survival analysis showed that those with the highest tertile of CSF PC were less likely to worsen their cognitive status in at least 18 months follow up (p = .042). A similar trend was observed with 4-HNE lysine although not significant. Findings were not affected by age or ART.
Conclusions/Relevance: In the ART era, oxidative stress as determined by CSF PC levels may represent an early marker for the progression of HIV-associated cognitive impairment. High baseline PC levels had a predictive value among women with stable mild cognitive impairment. The influenza pandemic of 1918/1919 was a unique event in recorded history, costing on the order of 50 million lives within the time span of only several months. The virus is obviously extinct, but the advent of reverse genetics techniques for negative strand RNA viruses (a family of viruses which includes the influenza viruses) makes it possible to reconstruct infectious influenza viruses. Based on the nucleotide sequence that was obtained from RNA fragments present in lung samples of victims of the 1918 influenza virus, we succeeded in rebuilding the extinct pandemic virus entirely from commercially available oligonucleotides. This virus turned out to be highly virulent in the mouse model, more than any other human influenza virus strain tested. It also was shown to be highly pathogenic for chicken embryos and grew in human tissue culture cells to high titers. On the other hand, the 1918 virus was shown to be sensitive to FDAapproved antivirals (amantadine as well as the neuraminidase inhibitor oseltamivir). We were also able to show that vaccines worked perfectly well in protecting mice against a challenge with a virus containing the 1918 hemagglutinin and neuraminidase genes. We also postulate that the human population, having experienced infections with currently circulating H1N1 viruses, is partially immune to a 1918 or 1918-like virus. The availability of the 1918 virus will help us to better understand the molecular basis of virulence and the mechanisms by which pandemic influenza viruses are transmitted from human to human and from one species to another. In addition, these studies will expand our knowledge of the biological and molecular properties of pandemic influenza viruses in general and this in turn will provide us with better prevention and treatment strategies for the future. Onset and progression of HIV-associated dementia (HAD) is linked with increased levels of proinflammatory mediators in the CNS and those of markers of platelet activation. Here we show that the circulating levels of sCD40L are elevated in cognitively impaired HIV-1-positive subjects, and candidate HIV-1 neurotoxin, platelet-activating factor (PAF), triggers the synthesis of soluble CD40 ligand (sCD40L) in primary cultures of human platelets. Interestingly, this increase in sCD40L release from platelets, was profoundly blocked by addition of an inhibitor of MLK-3 (CEP1347). We also show that recombinant CD40L promotes the ability of HIV-1 Tat to hyper-activate monocytes and microglial cells, in MLK-3-dependent manner, leading to the secretion of neurotoxic inflammatory mediators (notably, TNFα). CEP1347 also enhanced survival of neurons after exposure to Tat, whereas, immunodepletion experiments revealed that TNFα is essential for the neurotoxic effects of conditioned medium recovered from Tat/CD40L-treated monocytes. Collectively, these observations corroborate with our previous findings, that PAF acts as an initiator step in HIV-1 neuropathogenesis, and suggest that HAD may be characterized by a positive feedback loop between platelet activation and monocyte/microglial stimulation. Our model also predicts that the drug regimens (such as the MLK-3 inhibitor, CEP1347, currently in development for Phase 1 trials of neuroprotection in patients with HIV-1 infection and cognitive deficits), which simultaneously target activation of both platelets and monocytes/microglia, may of therapeutic value in the treatment of HAD.
S.13
Novel expression of PINCH in the CNS and its potential as a biomarker for HIV-associated neurodegenerative processes T Dianne Langford, Introduction: qfMRI has been used to study the basic physiology of cortical regions of the brain in health controls. Simultaneous acquisition of the blood oxygen level dependent (BOLD) and CBF responses during functional activation and mild hypercapnia experiments allows for non-invasive determination of CMRO2 during a functional task. We used qfMRI to determine if physiological responses within the visual cortex to a simple flashing checkerboard task were different within acute and chronic HIV infection. Methods: 20 seronegative healthy controls and 9 early infected HIV+ subjects (less than one year after known seroconversion) and 9 chronically infected HIV+ subjects (more than one year after seroconversion) were studied at 3 T using QUIPSSII/PICORE ASL technique with a dual echo spiral k-space acquisition 8th International Symposium on NeuroVirology Oral Presentations 11 of CBF and BOLD data. All subjects initially received two trials of a 5% CO2 gas mixture for 3 minutes with 4 minutes between CO2 challenges. Mild hyperpcapnia was used to manipulate CBF changes independent of CMRO2. During four subsequent activation scans, subjects viewed a flashing checkerboard stimulus at 8Hz. Each functional scan consisted of 4 trials using a block-design stimulus (20 sec on, 60 sec off). A region-of-interest was drawn for each subject corresponding to the visual cortex which included not only V1 but higher visual association areas. From this region trial-averaged CBF and BOLD responses were obtained for the functional activation paradigm and for mild hypercapnia. CMRO2 values were subsequently calculated using a standard equation. An analysis of variance (ANOVA) was performed for both measured (CBF and BOLD) and calculated (CMRO2) values with subsequent paired t-test performed with p values significant if p < 0.05.
Results: Both CBF and BOLD responses were reproducibly observed within the visual cortex for functional stimulation and mild hypercapnia in HIV+ subjects (early and chronic) and seronegative controls. Changes in CBF and CMRO2 but not BOLD for functional activation were significantly greater within HIV+ subjects compared to seronegative controls. In particular these changes in CBF and CMRO2 were observed in early infected HIV+ patients and remained elevated in chronically infected HIV+ subjects. There was no correlation between nadir CD4, current CD4, or HIV RNA levels and qfMRI measures within HIV+ subjects.
Conclusions: HIV has significant effects on CBF and CMRO2 even within cortical regions. These findings are consistent with previous evidence of brain dysfunction early in HIV infection (e.g., Grant et al. 1987 ) demonstrated by neuropsychological testing and electrophysiological measures. These results extend previous work by suggesting that cerebral metabolic dysfunction is a final common pathway for both neuropsychological and electrophysiological disturbances in HIV-infected patients qfMRI may therefore act as a non-invasive surrogate biomarker for assessing effects of HIV in the brain.
S.16
Alteration Studies suggest that opiates may exacerbate the neurological complications of HIV-1 through direct actions in the CNS. Our goal is to determine the effects of mopioid receptor (MOR) agonists on the signaling pathways activated by CXCR4-one of the major HIV coreceptors, which also plays critical roles in neuronal survival and differentiation. In particular, we use in vitro and in vivo approaches to establish the effects of MOR agonists on the coupling of CXCR4 to neuronal survival mechanisms. Our data show that longterm treatment of rat primary cortical cultures with DAMGO, morphine or endomorphin-1 inhibits activation of ERK1/2 and Akt by CXCL12-an effect that is not mediated by changes in CXCR4 levels on neuronal surface. Pretreatment with MOR agonists also prevents the neuroprotective action of CXCL12 in NMDAtreated cultures. MOR and CXCR4 are co-expressed in many cultured neurons suggesting a possible crosstalk between the two receptors. This is supported by GTPgS incorporation studies in rat brain slices and brain homogenates measuring levels of G-protein activation upon stimulation of CXCR4 or MOR. These studies also show that in vivo morphine treatments inhibit CXCR4-mediated G-protein activation. Experiments with glia-free cultures demonstrate that the inhibitory effect of opioids on CXCR4 signaling is independent of glia, and that opioid treatment blocks CXCL12-mediated phosphorylation on specific residues of the C-terminus of CXCR4, which is involved in receptor activation/desensitization. Down-regulation of phospho-CXCR4 was also found in brain tissue from HIV/HAD patients, suggesting that impairment of CXCR4 function by opioids may contribute to HIV neuropathology.
(Supported by NIDA: DA19808 and DA15014) We performed immunohistochemistry (IHC) for amyloid, Tau and a-synuclein on autopsy brain tissues from 35 HIV infected patients who have died on HAART. The regions studied included neocortex, subcortical white matter and basal ganglia. Light microscopy analysis of single label staining regional distribution was complemented by double immunofluorescent stainings to determine the subcellular distribution of protein aggregates and association with markers of neuronal degeneration and glial activation. Results: FDDNP-PET (targeting both b-Am and Tau aggregates) shows increased deposition in the brains of HIV patients with MCI (n = 3) compared to controls. The distribution of the FDDNP PET signal is quite different from that found in Alzheimer's disease patients imaged with the same ligand [2] . All three HIV subjects had increased binding in the posterior cingulated gyrus, and in the (parieto-temporal) Brodmann areas 7, 40, 39 and 22.
From the expanded autopsy studies we now have evidence that intra-neuronal deposition of b-AM (34 positive cases out of 35 studied), Tau and a-synuclein in the HIV brain is abundant and the distribution follows the axonal tracts. Ultrastructural analysis shows that 8th International Symposium on NeuroVirology Oral Presentations 13 intracellular b-AM is often found in structures consistent with autophagosomes. Conclusions: FDDNP-PET detects early signs of brain degeneration in aging HIV infected patients on HAART. Furthermore, our recent autopsy studies suggest that the distribution of abnormal protein aggregates associates with disruption of the axonal homeostasis like accumulation of hyperphosphorylated Tau, and increased expression of brain immunophilins. Since the incidence of minor cognitive impairment in HIV patients is on the rise, studies of abnormal intra-neuronal protein aggregation may help in monitoring a key mechanism of brain disease and design neuroprotective strategies. 
S.19
Opiates Identification of the signaling mechanisms that modulate the activity of the NMDA receptors in the brain may be translated into the development of newer, more effective therapies for the prevention and treatment of HIVE, which continues to manifest significant morbidity and mortality among HIV-1 infected patients especially those who are addicted to opiates.
S.20
Nonhuman primate models of drug abuse and AIDS Michael A Taffe and Howard S Fox
The Scripps Research Institute
Determination of the mechanisms by which chronic exposure to drugs of abuse may alter the progression of HIV/AIDS requires animal models. The rhesus monkey in particular offers well established SIV models and has been employed in numerous studies of abused drugs. Nevertheless evaluation of the combined effects of immunodeficiency viruses and specific drugs of abuse requires close consideration of the criteria which should be used to select models of drug abuse. Consideration of routes of administration, dose and exposure schedules for individual recreational drugs may be critical to establishing relevant risks of co-exposure with immunodeficiency virus infection. Recent studies on the impact of chronic exposure to alcohol and methamphetamine, respectively, on the progression of SIV infection in rhesus monkeys will be discussed. The chemokine receptor CXCR4 is involved in HIV infection and contributes to HIV neuropathology in a direct and indirect manner. It has been suggested that abnormal activation of CXCR4 alters neuronal/glial signaling causing neuronal damage, whereas proper CXCR4 signaling promotes neuronal survival. Previous work from our group showed that dysregulation of cell cycle proteins, namely the CDK/Rb/E2F pathway, is involved in the neurotoxicity induced by X4-using HIVgp120s; we also reported that E2F1 and its transcriptional target cdc2 (also known as cdk1), are up-regulated in the brain of HIV/HAD patients. This study aims to establish the role of cdc2 in gp120-induced neuronal injury and determine the molecular mechanisms involved in neurotoxicity. We report that expression of a Cdc2 dominant negative mutant in rat cortical neurons rescues them from HIVgp120-induced apoptosis. Also, down-regulation of cdc2 expression by shRNA in human cell lines reduced phosphorylation of apoptotic proteins downstream cdc2. Furthermore, as recent evidence suggests that Cdc2 is implicated in the regulation of intracellular Ca2+ homeostasis via phosphorylation of IP3 receptors, we are currently testing the hypothesis that cdc2 may also lead to aberrant Ca2+ signaling in neurons, by using calcium imaging and IP3-uncaging. Alterations of Ca2+ homeostasis by gp120 and other HIV-1 proteins are well-documented, and know to affect neurotransmission and neuronal survival, which lead to HIV-associated neuronal deficits. These studies show the importance of cdc2 in gp120-induced neurotoxicity and suggest that therapeutic approaches aimed at preventing stimulation of cdc2 or its targets in neurons may turn useful in HIV neuropathology. (Supported by NIH grants DA 19808 and 15014 to OM). In humans, a primary infection with Herpes simplex virus type-1 (HSV-1) is followed by a lifelong viral persistence in the sensory neurons of the cranial nerve ganglia, especially in the trigeminal ganglia (TG), and less frequently in the geniculate (GG) and vestibular ganglia (VG). In some individuals HSV-1 reactivates repeatedly from the TG and causes 'herpes labialis'. In contrast, reactivation from the GG and VG is rather a once-in-a-lifetime event.
S.22 T-cell infiltrates in HSV-1 latently infected human geniculate ganglia
Immunohistochemical and quantitative RT-PCR studies in the TG have revealed that HSV-1 latency is accompanied by an active chronic immune response composed of CD8+ T-cells showing an effector memory phenotype. Although the infiltrating T-cells reflect an active immune response, it is not clear whether the T-cells control viral latency and reactivation or whether they represent an inflammatory residue after the frequent silent or overt reactivations in the TG.
In the present study, using immunohistochemistry, we found that T-cells are also present in the GG where the latency-associated transcript (LAT) was detectable by in situ hybridization. In the VG no T-cells could be found and LAT was detectable only after amplification by RT-PCR. Hence we suppose that the T-cell infiltration in the cranial nerve ganglia monitors HSV-1 latency and does not only represent an inflammatory sequel of a previous reactivation.
S.23
HIV-1 and cytokine (IFN-γ /TNF-α) synergy in CXCL10 release from astrocytes: implications in HIV-associated dementia Rachel Williams, Navneet Dhillon, Fuwang Peng, and Shilpa Buch
University of Kansas Medical Center
There are 40 million people world wide infected with Human Immunodeficiency Virus-1 (HIV-1). Shortly after infection, HIV-1 penetrates the brain and can eventually cause HIV-1 associated CNS disease, of which HIV-associated dementia (HAD) is the most severe manifestation. HIV encephalitis (HIVE), the pathologic correlate of HAD is characterized by astrogliosis, cytokine/chemokine dysregulation, and neuronal degeneration. The severity of HAD/HIVE correlates better with the presence of activated astroglial and microglial cells rather than with the presence and amount of HIV-1 infected cells in the brain. Also, correlated with the pathogenesis of HAD/HIVE are the increased levels of the proinflammatory cytokines, IFN-γ and TNF-α. These two cytokines are released by activated immune cells and have the ability to synergize with other cellular factors and HIV-1 viral proteins resulting in increased inflammation and a more severe disease state. Astrocytes, the most populous cell type within the brain, are activated not only by IFN-γ and TNF-α, but also by HIV-1. Once activated, astrocytes provide an important reservoir for the generation of inflammatory mediators including CXCL10, a neurotoxin and chemoattractant. CXCL10 is implicated in the pathophysiology of HAD since high levels of CXCL10 are also correlated with disease severity. The underlying central hypothesis of these studies is that the interplay of viral and cellular factors in astrocytes can result in the synergistic induction of CXCL10 expression resulting in neuronal degeneration. Our preliminary studies suggest a synergistic induction of CXCL10 protien in astrocytes exposed to HIV-1, IFN-γ and TNF-α. We observed that the HIV-1 proteins nef and tat were the key determinants involved in synergy with IFN-γ and TNF-α. Transcriptional and translational regulatory mechanisms involved in the synergistic enhancement of CXCL10 will be discussed.
This could have possible implications for enhanced CNS disease because of the neurotoxic functions of CXCL10 and its ability to enhance viral replication. Thus understanding the cellular and molecular mechanisms involved in the induction of proinflammatory responses by astrocytes is critical to the development of interventional therapies for the treatment of HAD.
S.24
The role of JC virus minor capsid proteins in the viral lifecycle Megan L Gasparovic and Walter J Atwood Brown University JC virus (JCV) is a human polyomavirus for which 70% of the human population is seropositive. It is responsible for the fatal demylinating disease Progressive Multifocal Leukoencephalopathy (PML). JCV contains an icosahedral capsid that consists of 72 pentamers of the major capsid protein Vp1 with a minor coat protein Vp2 or Vp3 in the center of the pentamer. It is known that Vp1 contributes to virus tropism through receptor interactions. However, little is known about the role the minor coat proteins in pathogenesis. Using site-directed mutagenesis we show that both Vp2, the myristylation site on Vp2, and Vp3 are necessary for the correct packaging of viral DNA. We suspect that these proteins also play critical roles early in infection and have engineered tags in Vp2 and Vp3 to facilitate their detection in infected cells. The tagged viruses are viable and Vp2 and Vp3 localize to subcompartments within the nucleus. Co-localization studies with Vp1 show that Vp1 is uniformly distributed in the nucleus and Vp2 and Vp3 are excluded from the peripheral margins of the nucleus. We are currently using the tagged virions to study the trafficking of virus from the plasma membrane to the nucleus with the goal of understanding when and where the minor capsid proteins become exposed in the cell.
S.25
Transmigration of HIV infected monocytes/macrophages and lymphocytes into the central nervous system Clarisa M Buckner, 1 Peter J Gaskill, 1 Eliseo A Eugenin, 1 and Joan W Berman Human immunodeficiency virus 1 (HIV-1) invades the brain and results in neurologic dysfunction in a large percentage of individuals. Even with adequate suppression of systemic virus due to therapy, central nervous system (CNS) disease continues to evolve. Both the penetration of HIV into the brain and the subsequent damage are thought to be mediated by transmigration of infected monocytes across the blood brain barrier (BBB). The number of activated macrophages in the CNS appears to be a more reliable predictor of HIV associated cognitive impairment than viral load, suggesting that monocyte infiltration and CNS damage are tightly correlated. Monocyte/macrophage trafficking is of interest in studies of the pathogenesis of HIV infection because of their ability to cross the BBB, to elaborate factors that are harmful to the CNS, and to establish viral reservoirs. Monocytes may circulate in the peripheral blood for 1-3 days before entering and differentiating into macrophages in the brain. It is important to determine the phenotypic markers and the stage of maturation of monocytes as they enter the CNS, with the ultimate goal of therapeutic intervention to limit CNS infection and inflammation associated with NeuroAIDS. We first designed experiments to establish the optimal culture system for human peripheral blood mononuclear cells (PBMC) that promote monocyte/macrophage survival and examined the expression of specific phenotypic markers as cells mature in culture. Flow cytometry was used to determine monocyte/macrophage maturation using antibodies to CD14, CD71, CD68 and CD16. We found Macrophage Colony Stimulating Factor (MCSF) supports the survival of CD14+ isolated monocytes and their expression of maturation markers under non-adherent HIV-associated dementia (HAD) is a common neurological complication of AIDS that involves activation of macrophage/microglial cells in the brain, with subsequent release of toxins including proinflammatory cytokines that lead to neuronal death. In addition to direct infection, uninfected bystander macrophages can be activated by viral proteins such as the Env glycoprotein gp120 to induce cytokine production. Interleukin-1 beta (IL-1b) is one of the proinflammatory cytokines upregulated in brain, CSF and blood of HAD patients. Although gp120 has been reported to induce IL-1b production by macrophages in vitro, the signal transduction pathways responsible have not been defined. In this study, we set out to elucidate the mechanisms mediating gp120-induced IL-1b release by primary human monocyte-derived macrophage (MDM). Recombinant gp120 from CCR5-using (R5) HIV-1 stimulated IL-1b production by MDM as measured by ELISA in both time-and concentration-dependent manner. Which are the compounds that inhibit the replication of these viruses, and could eventually be useful in the treatment of the neurological disorders associated with these viruses? These are: (i) for polyomavirus, acyclic nucleoside phosphonates (such as cidofovir and derivatives thereof); (ii) for HSV, acyclic guanosine analogues (such as acyclovir, ganciclovir and penciclovir), and, putatively, helicase-primase complex inhibitors, (iii) for HHV-6, a variety of both acyclic nucleoside phosphonates and non-nucleoside types of compounds (i.e. CMV423); (iv) for polio-and other enteroviruses, a number of capsid binders as well as protease, polymerase, 3A and 2C inhibitors; (v) for flaviviruses, interferons and interferon inducers (such as ampligen); (vi) for (-)RNA viruses, IMP dehydrogenase inhibitors (such as ribavirin) and SAH hydrolase inhibitors (such as 3-deazaneplanocin A); (vii) for arena-and bunyaviruses, the pyrazine derivative T-705 (which has also been known for its anti-influenza virus activity); and (viii) for HIV, the now more than twenty compounds which have been formally approved for clinical use and could be administered in various drug combination regimens.
S.28
Efficacy of antiretroviral therapy in the brain Ronald J Ellis
UCSD HIV Neurobehavioral Research Center
Epidemiologic evidence provides the best support for HAART's beneficial impact on primary HIV CNS disease. Rabies virus is the etiological agent of an acute encephalitis, which in absence of post exposure treatment is fatal in almost all cases. Virus lethality rests on its ability to evade the immune response. Here, we analyzed the role of the immuno-inhibitory molecule B7-H1 in this virus strategy. We showed that in the brain and spinal cord of mice, rabies virus infection resulted in significant up-regulation of B7-H1 expression, which is specifically expressed in infected neurons. Correlatively, clinical rabies in B7-H1−/−mice is markedly less severe than in wild type mice. B7-H1−/−mice display resistance to rabies. Virus invasion is reduced and the level of migratory CD8 T cells increases into the nervous system, while CD4/CD8 ratio remains unchanged in the periphery. In vivo, neuronal B7-H1 expression is critically depending on TLR3 signalling and IFN-type 1 since TLR3−/− micein which IFN-beta production is reduced-showed only a limited increase of B7-H1 transcripts after infection. These data provide evidence that neurons can express the co-inhibitory molecule B7-H1 after viral stress or exposure to a particular cytokine environment. They show that the B7-H1/PD-1 pathway can be exploited locally and in an organ specific mannerhere the nervous system-by a neurotropic virus to promote successful host invasion.
S.31
Paroxetine treatment for HIV-mediated neurodegeneration Joseph P Steiner, Carlos Pardo-Villamizar, Daniella Asch, Norman J Haughey, Justin C McArthur, and Avindra Nath
Department of Neurology, Johns Hopkins University School of Medicine
The prevalence of both of HIV sensory distal neuropathy and HIV-Dementia has been increasing as effective antiretroviral therapy allows patients to live longer These complications are a result of oxidative stress and neurotoxicity that results directly from HIV infection and from the exposure of CNS neurons to toxic viral proteins, such as Tat and gp120. These toxicities are complicated and exacerbated by aging and prevalent drug abuse in this patient population. We have mimicked the co-morbid effects of drugs of abuse on neurotoxic HIV-1 Tat and gp120 in in vitro assays by combining cocaine and/or morphine with Tat and gp120. Thus, identification and development of therapeutic strategies to protect against this neuronal damage and the ensuing clinical deficits is a major unmet medical need. We have screened more than two thousand compounds that included FDA approved compounds and natural products for protective efficacy against oxidative stress-mediated neurodegeneration and identified selective serotonin reuptake inhibitors (SSRIs) as potential neuroprotectants. Numerous SSRIs were then extensively evaluated as protectants against neurotoxicity as measured by changes in mitochondrial potential, neuronal cell death and induction of nitric oxide synthase elicited by HIV Tat and gp120 in primary rat mixed hippocampal cultures in the presence and absence of cocaine and/or morphine. While many of the SSRIs demonstrate neuroprotective actions, we find that paroxetine is potently neuroprotective in this cell culture model, but may require concentrations greater than those required for inhibition of The roles of heredity and environment as disease determinants have been debated for millennia. The emphasis on one or the other has largely been driven by technology. Despite the periodic appearance of new pathogens, we have likely collected much of the "low hanging fruit" (microbes readily associated with diseases). The challenge now is to understand those disorders that reflect the interaction of environmental factors (microbes, toxins, other stressors) with susceptibility genes. The objectives of our research program are to investigate the role of infectious agents in the pathogenesis of acute and chronic diseases; dissect the mechanisms by which microbes and host responses result in damage and dysfunction; and find strategies to reduce the burden of morbidity and mortality due to infectious diseases. I will discuss a staged strategy for diagnosis of infection and pathogen discovery, efforts in zoonotic surveillance, and future perspectives based in prospective birth cohorts.
S.33
Activating the maternal immune system causes changes in the offspring resembling those in Schizophrenia and autism Paul H Patterson
California Institute of Technology, Pasadena, CA 91125
Maternal viral infection is associated with increased risk of schizophrenia and autism in the offspring. In a mouse model based on this risk factor, we found that respiratory infection with influenza virus leads to behavioral abnormalities in the adult offspring. These behaviors are consistent with abnormalities seen in schizophrenia and autism, including enhanced anxiety in the open field (OF), as well as deficits in social interaction (SI), latent inhibition (LI) and prepulse inhibition (PPI). The latter is corrected by anti-psychotic and exacerbated by psychomimetic drugs. The adult offspring display neuropathology in the cortex and hippocampus similar to that found in schizophrenia and a localized deficit in Purkinje cells that resembles that in autism.
The cause of these various abnormalities is the maternal response to viral infection, as treatment of uninfected, pregnant mice with the dsRNA, poly(I:C), which evokes an anti-viral-like immune response, also induces OF, SI, PPI and LI deficits and the Purkinje cell deficit in the offspring.
Exploring potential mediators of these effects revealed that injection of the cytokine IL-6 in normal pregnant mice causes PPI and LI deficits in the offspring, while co-injection of anti-IL-6 antibody with poly(I:C) in pregnant mice blocks the effects of maternal immune activation on the behavior of the offspring. Moreover, the offspring of poly(I:C)-treated IL-6 knockout mice do not display behavioral abnormalities. Furthermore, maternal anti-IL-6 blocks the changes in gene expression in the brains of adult offspring that are caused by maternal poly(I:C) treatment. Therefore, IL-6 is a key mediator of the effects of the activated maternal immune response on fetal brain development.
Supported by the NIMH, and the McKnight, Autism Speaks, and Cure Autism Now foundations. Neonatal Borna disease virus (BDV) is a neurotropic negative-strand RNA virus that establishes persistent infection in the rat brain associated with microglial activation and damage to the certain neuronal populations. Since persistent BDV infection of neurons in vitro is non-cytolytic, activated microglia may be responsible for neuronal cell death in vivo. However, the mechanisms whereby microglia are activated and produce neuronal damage remain unknown. We found that neither purified virus nor BDV-infected neurons alone were able to activate microglia in vitro. In contrast, microglia were activated in organotypic BDV-infected mixed neuron-astrocyte-microglia cultures, suggesting an importance of interactions between infected neurons, astrocytes and microglia for neuroinflammation to occur. Co-culturing infected and uninfected primary neurons and glia cells in various combinations confirmed this suggestion by demonstrating that conditioned media from BDVinfected neurons activated uninfected astrocytes, which, in turn, were able to activate microglia. Remarkably, microglia activation was observed in the absence of overt neuronal toxicity in culture and two weeks before any signs of neurodegeneration in vivo. Taken together, our findings provide the first evidence that activation of microglia initiated by interactions between persistently BDV-infected neurons and uninfected astrocytes may be a leading event in chronic neuroinflammation that results in neurodegeneration in selected neuronal groups.
S.34 Inhibition of the IFN-α/β response by mouse hepatitis virus (MHV) at multiple levels
S.37
Association of HSV and amyloid precursor protein during intraneuronal transport: a time-lapse live imaging study Serum procalcitonin is being investigated to distinguish bacterial from viral meningitis and may be useful in association with CSF cell count and glucose concentration in making the decision to discontinue empiric therapy for meningitis.
Dexamethasone is now part of the recommended empiric therapy of bacterial meningitis in children and adults as clinical trials have demonstrated its efficacy in reducing neurological sequelae and mortality. Concerns about the penetration of vancomycin through noninflamed meninges have been addressed by the recommendations for increasing the parenteral dose and the use and safety of intraventricular vancomycin. Listeria monocytogenes is increasingly recognized as a meningeal pathogen in immunocompetent individuals, and as the etiological organism of brainstem encephalitis:
There have been two significant advancements in the diagnosis and therapy of fungal infections:
Serum and CSF galactomannan are helpful in the diagnosis of fungal meningitis. Many experts now recommend high dose oral fluconazole as initial therapy for Coccidioides immitis meningitis.
Tuberculous meningitis may present as either a subacute meningitis with symptoms evolving over weeks, or a fulminant meningitis with the rapid development of coma. The development of a Mycobacterium tuberculosis ribosomal RNA test that can be performed rapidly on CSF is a critical advancement in the diagnosis of tuberculous meningitis. There is increasing understanding that a mildly decreased CSF glucose concentration in association with a CSF lymphocytic pleocytosis is evidence of tuberculous meningitis. Patients with acute fulminant tuberculous meningitis may initially have a CSF polymorphonuclear pleocytosis. Empiric therapy for tuberculous meningitis is warranted in patients with symptoms of meningitis, a CSF pleocytosis of either polymorphonuclear leukocytes or lymphocytes and a mildly decreased (30-40 mg/dl) CSF glucose concentration.
All of the above will be discussed with an emphasis on how they have changed the management of the patient with suspected bacterial, tuberculous or fungal meningitis. Several studies have shown a significant association or a pathogenic rationale for MSRV and its HERV-W genetic family in MS pathogenesis. The envelope protein (ENV-MSRV or Syncytin) was found to display pro-inflammatory activities both in vitro, in human mononuclear cells and in vivo, in a humanized severe immuno-deficient mice either with an hyperacute Tlymphocyte mediated lethal syndrome, either with an ENV-induced "MBP EAE" model (Cf. abstract on preclinical model). MSRV RNA from extracellular virion was significantly detected in association with MS in patient's cerebrospinal fluid (CSF) and plasma. Prognosis of MS evolution was evidenced by the retroviral load in CSF at disease onset in 3 and 6 years retrospective studies. Numerous confirmatory epidemiological and experimental data from independent groups using various techniques now provide strong evidence of association with MS. The pathogenic ENV Protein itself ha been evidenced in post-mortem brain plaques by different groups as well, but not yet in living patients.
We have thus developed an immunoassay with specific monoclonal antibodies for the detection of HERV-W antigens in human blood. Our results from a multicenter study with externalised and blind testing of HERV-W ENV antigenaemia in blind-coded serum, detected 73% of positive cases in about 80 MS patients, but not in 36 healthy controls. These results are thus providing the last missing link between virion RNA detection in MS serum or CSF and the immunotoxic ENV protein encoded by HERV-W elements.
This ELISA immunoassay is now dedicated to patients' follow-up in an extension of this first multicenter study. It also represents a positive inclusion criterion of MS patients for targeted therapeutic approaches under development (Cf. Pre-clinical therapeutic abstract). We have studied MSRV in MS patients in various stages of the disease (1), in follow up evaluations (2-3), as well as in the conversion of optical neuritis to full blown MS (4), in comparison to healthy and pathological controls. In all cases, the data showed a striking parallelism between MS behaviour and MSRV presence and/or load in patient's blood and spinal fluid. We found also that MSRV/HERV-W is highly expressed in MS brains, and that its env protein accumulates particularly in the core of active lesions, in cells resembling astrocytes (5) . Cultured peripheral blood mononuclear cells from MS patients and from MSRV(+) healthy individuals release free virus in culture fluids (6) , and MSRV production is stimulated by cell treatment with cytokines shown to be detrimental in MS patients, such as TNFalpha, IL-6 and interferon (IFN)gamma, while IFNbeta, that is used in MS therapy, causes a dramatic reduction of MSRV yields.
S.42 Multiple sclerosis (MS)-associated retrovirus (MSRV) is inhibited during interferon-beta-therapy of MS patients and behaves as progression biomarker
Based on these premises, also to investigate whether detection of circulating MSRV can constitute a biomarker of MS progression and therapy efficacy, we performed a longitudinal study on MS patients with relapsing-remitting disease, during one year of therapy with IFNbeta, by clinical examination and detection of cell-free MSRV and viral load in the blood by MSRVenv-specific fully quantitative real time RT-PCR. Routine clinical examination and blood withdrawal were blindly performed at study entry and every three months.
Results showed that at study entry MSRV load in the blood was directly related to MS duration; IFN therapy determined a complete clearance of the virus from blood; one patient had strong progression with therapy failure, that was accompanied by total MSRV rescue.
It is unknown so far whether MSRV is a MS cofactor or epiphenomenon. Our findings suggest that evaluation of plasmatic MSRV can be considered the first prognostic marker for the individual patient, to monitor disease progression and therapy outcome. The past decade has seen the acceptance of conceptual descriptions of the central nervous system (CNS) as dynamic rather than rigidly deterministic, both in response to injury and through adult life. Localized stores of multipotent neuroepithelial progenitor cells (NEP) proliferate and then differentiate in response to growth factors or cell surface contact influences, giving rise to specialized, lineage-committed precursor cells, which in turn give rise to both glia (astrocytes, oligodendrocytes) and neurons. While NEP are most abundant during fetal development of the CNS, selfrenewing populations continue to exist in the adult mammalian CNS, found predominantly in the brain subventricular zone and hippocampal dentate gyrus. Endogenous neurogenesis originating with these populations may be an important contributor to cognitive and behavioral function. However, inflammation, precipitated by CNS injury or viral infection, may influence neurogenesis in a complex manner. Chronic inflammation can lead to defective proliferation of neural precursors as well as failure of neuronal lineage differentiation. Thus inflammation may impair neurogenesis. Pro-inflammatory cytokines may inhibit proliferation of NEP but may also actually enhance neurite outgrowth and neurite development under differentiation conditions.
HIV-1 infection in the CNS represents the type of chronic viral infection that is capable of impacting the proliferation or differentiation of NEP. In hippocampal tissue specimens from HIV-associated dementia patients, numbers of proliferating NEP were reduced by 75% when compared to patients without dementia. In vitro studies have demonstrated that exposure to HIV-1 envelope protein reversibly inhibits human NEP proliferation. However, HIV-1 exposure does not appear to inhibit neuronal fate determination or the proliferation of neuronal-committed precursors during differentiation of NEP. But neurons developing in the microenvironment of HIV-1 exposure "fail to thrive," even without direct infection of neural cells and without neuronal apoptosis. HIV-1 exposure may impair maturation of neuronal precursors in that late or postmitotic antigens (NF-L, Hu) are up to 40% lower when virus exposure commences with the start of differentiation. Neuronal microtubule antigen β-III-tubulin is up to 50% lower when virus exposure occurs during the first five days of differentiation. Neurofilament proteins, particularly NF-L, may be especially sensitive to viral exposure. NF-L shows depressed levels with exposure to envelope gp120 from HIV-1(SF2) as well as the intact HIV-1(SF2) virus. NF-L may have a role as CSF biomarker for neuronal dysfunction in HIV infection if it can be correlated with cognitive impairment.
Pathophysiologic mechanisms underlying neuronal "failure to thrive" may include non-viral factors such as oxidative and/or nitrosative stress, genetic susceptibility to oxidative stress or inflammation as mediated by apolipoprotein E, and alteration of cell responsiveness to neurotrophins due to factors secreted by immune-activated cells in the microenvironment of chronic viral infection. These indirect effects of HIV infection may impact endogenous neurogenesis and neuronal survival. As such, HIV-1 infection presents both clinical and biological parallels to other brain injury states such as trauma, radiation, or ischemia.
S.44
Lineage directed differentiation of human brain derived progenitor cells alters JC Virus and HIV-1 fate of infection: Implications of neuropathogenesis Eugene O Major, Lynnae Schwartz, and Maria Chiara Monaco
Laboratory of Molecular Medicine and Neuroscience NINDS, NIH Bethesda, Maryland
We have identified, isolated, and continually propagated neural progenitor cells from the developing human brain. These cells, NPCs, can be directed to multiple lineage pathways including neurons, astrocytes and oligodendrocytes by introduction of different factors into the cell culture medium. Treatment of NPCs with either the human polyomavirus, JCV, or HIV-1, resulted in only a small fraction of the these cells showing infection. However, either at the time of delivery of virus or after 4 or more days after virus treatment, if the cells were directed to an astrocyte lineage, there was a substantial increase of virus synthesis indicating differentiation induced activation of either JCV or HIV-1. Differentiation toward a neuronal lineage reduced viral synthesis quickly until the infection was HIV can reside in the brain for many years. While astrocytes are known to tolerate long-term HIV infection, the potential of HIV to persist in other neural cell types is unclear. Recent studies demonstrate HIV invasion of cultured fetal brain-derived neural progenitor cells and occurrence of HIV markers in nestin-positive cells in pediatric brain tissues. Here we investigated whether HIV can establish long-term infection in human neural progenitor populations.
As experimental system we used the human neural stem cell line HNSC.100, cultured either as selfrenewing neural progenitor populations or under conditions known to induce differentiation to astrocytes. Several features were identified that allow reliable functional and phenotypical distinction of HNSC progenitor and astrocyte populations.
HNSC-prognitor populations were exposed to HIV-1 and various parameters of HIV infection were monitored for over 100 days. Analysis of HIV proviral copy numbers by quantitative real-time PCR confirmed persistence of HIV proviral genomes for the entire observation period. HIV-infected progenitor cultures released moderate amounts of HIV for over 60 days, after which HIV release declined. However, expression of early HIV gene products was still apparent at later time points. Differentiation of HIV-infected progenitor populations to astrocytes was associated with transient activation of HIV production. Long-term HIV infection of progenitor populations upregulated expression of GFAP and led to measurable, albeit moderate, changes in cell morphologies.
Our studies support persistence of HIV in neural progenitor populations and indicate that HIV persistence has the capacity to alter cellular properties in neural progenitor populations.
S.46
The homeostatic pressure exerted by stem cells in degenerative or injured CNS environments Evan Y Snyder
Burnham Institute for Medical Research
Dr. Snyder has most recently been studying an intriguing phenomena with possible therapeutic dividends that has begun to emerge from his observations of the behavior of neural stem cell (NSC) clones in various mouse and primate models of CNS injury & degeneration. During phases of active neurodegeneration, factors seem to be transiently elaborated to which NSCs may respond by migrating (even long distances) to degenerating regions & attempting to restore homeostasis. This may include differentiating towards the replacement of degenerating neural cells of multiple types, not only neurons but also requisite non-neuronal "chaperone" cells, all of which are essential for the proper development and reconstitution of function. NSC's are drawn to inflammatory niches. These "repair mechanism" may reflect the reexpression of basic developmental programs (particularly during temporal "windows" following injury) that may be harnessed for therapeutic ends. There is an enormous amount of "programmed" cross-talk between stem cells and the milieu that add complexity but also enrich therapeutic promise to the system. In addition, NSCs in their native state (as well as following genetic-engineering) may serve as vehicles for protein delivery allowing for the possibility of simultaneous cell replacement & gene therapy (e.g., with factors that might enhance differentiation, neurite outgrowth, connectivity, neuroprotection, antiinflammation, anti-scarring, and angiogenesis).
Cell-cell contact with communication through gap junctions appears to represent another mode of crosstalk. Multi-model approaches to most neurological conditions are likely required. The stem cell may serve as the "glue" for these. When combined with certain synthetic biomaterials, NSCs may be even more effective in "engineering" the damaged CNS towards reconstitution. Not only gene expression programs, but also an epigenetic chromatin modification programs seem critical for dictating plasticity and potency. These chromatin structures appear to influence the expression of various stemness genes, including some novel zinc finger proteins that influence the unfolding of various developmental programs along the continuum from pluripotence (as ES cells) to multipotence (as somatic stem cells, e.g., NSCs) to cell type commitment (e.g., as neural cell types).
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HIV-1-infected and/or immune-activated macrophages affect human fetal cortical neural progenitor cell proliferation and differentiation through TNF-α Hui Peng, Nicholas Whitney, and Jialin C Zheng (NPC). Changes in neurogenesis have been associated with multiple neurodegenerative disorders, but how neurogenesis is affected during HIV-1 associated dementia (HAD) has not been fully addressed. Here we test the hypothesis that HIV-1-infected and/or immune-activated macrophages affect NPC proliferation and differentiation through the regulation of cytokines. Data shows that LPS-activated human monocyte-derived macrophages (MDM) conditioned medium (LPS-MCM) induced a substantial increase in NPC proliferation. HIV-infected MCM (HIV-MCM) did not show a significant effect but HIV-infected and LPS-activated MCM (HIV/LPS-MCM) induced most significant NPC proliferation. Moreover, LPS-MCM and HIV/LPS-MCM decreased σ -III-tubulin and increased GFAP expression, indicating inhibition of neurogenesis and increase of gliogenesis. The increase of NPC proliferation and gliogenesis correlated with an increased production of TNF-α and IL-1σ by infected/activated MDM. Although both IL-1σ and TNF-α induced NPC proliferation and gliogenesis, these effects were only partially abrogated by soluble TNF-α receptors R1 and R2 (TNF-R1R2), but not by the IL-1 receptor antagonist (IL-1ra), indicating that the HIV-1-infected/LPS-activated MCMmediated effect is partially through TNF-α. TNF-α induced an increase of the inhibitory bHLH transcription factor Hes1 and a decrease of the bHLH determination factor Mash1 expression in a dose dependent manner, suggesting that TNF-α and MCM could directly regulate NPC cell fate through bHLH regulation. These observations provide evidence that HIV-1-infected and immune-activated macrophages affect neurogenesis through induction of NPC proliferation, inhibition of neurogenesis and activation of gliogenesis. Human immunodeficiency virus-1 (HIV-1) infection of central nervous system often results in mild to severe cognitive impairment and dementia due to significant neuronal death. The transactivator HIV-1 protein Tat, has been implicated in HIV associated neurological deficits. HIV-1 is classified into A-K clades that are unequally distributed in world of which HIV-1 clade B and C together account for almost all infections around the globe. Recently, clade B and C specific differences in Tat mediated cytokine and chemokine function have been demonstrated in human peripheral blood monocytes, however it is unknown if these differences affect neurons in human brain. The fact that HIV-1 clade C accounts for over 50% of HIV-1 cases in world today but its effect on neuropathogenesis is unknown, warrants an immediate need to investigate effect of Tat C on human neurons. We used human fetal brain derived neural precursor cell culture system to understand the pathological changes in terms of neuronal apoptosis, glial activation as well as elevation of certain inflammatory parameters. Our experimental data suggest that there are clade specific differences in Tat induced oxidative stress, degree of neuronal death which may be mediated due to disturbances in mitochondria membrane potential and release of cytochrome-c. We also observed that expression of Tat modulated cell growth and proliferation of neural precursor cells. We are currently studying the role of MAP kinase pathway as it plays an important role in neuronal cell function and differentiation. Our observations provide a better understanding of the neuropathogenesis and complications that may arise in human population infected with HIV-1C. Although JCV has been shown to infect lymphocytes, which can act as carriers into other organs, the time at which JCV enters the brain, and the mechanism of such entry are still unknown. Differences in the strain of JCV that is isolated from the kidney (CY) and the one that causes PML (Mad-1) suggest rearrangements in the control region during the time of latent and active infection. Another subject of controversy is the establishment of latency in the brain. To elucidate this question we have collected samples from 5 regions of 7 normal brains from individuals who died of non-neurological conditions, extracted DNA and PCR amplified viral sequenced from the early and late regions of JCV with specific primers. We found JCV DNA sequences in at least one region of all cases studied.
Furthermore, in order to demonstrate the cell type in which JCV is present, we have performed PCR amplification in laser-captured cells of different phenotypes labeled with specific markers for neurons, astrocytes and oligodendrocytes. Results from these experiments suggest that JCV establishes a latent infection in astrocytes and oligodendrocytes, but not in neurons. Finally, immunohistochemical studies showed no expression of viral proteins, T-antigen, capsid proteins (VP-1), and the accessory product Agnoprotein, ruling out productive infection.
Supported by Grants from the NIH awarded to KK and LDV.
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Non SIV-infected MAC387+ macrophages accumulate within encephalitic lesions of SIV-infected rhesus monkeys: MAC387 as a potential marker of disease HIV in humans and SIV in non-human primates cause immunodeficiency and can induce encephalitis. Monocytes/macrophages are targets of infection and play a key role in AIDS-associated neuropathogenesis. HIV/SIV enter the central nervous system (CNS) at primary infection (peak viremia), which corresponds to an increase of the number of CD14+CD16+ monocytes in peripheral blood and macrophages in the brain. We investigated the characteristics of macrophages present in brain lesions of SIV-infected CD8+ celldepleted rhesus macaques treated or not with anti-retroviral drugs (PMPA and RCV). SIV-infected untreated animals were sacrificed with AIDS, whereas the treated animals had histopathological evidence of SIV infection, but not AIDS. We focused on MAC387 expression, a marker of newly infiltrating monocytes/macrophages. PMPA/RCV-treated SIV-infected animals showed no encephalitis and no MAC387+ cells (n = 4). By contrast, we detected encephalitis in all non-treated SIV-infected animals that showed SIV RNA and an accumulation of MAC387+ cells within brain lesions around blood vessels (n = 4). Interestingly SIV-infected cells were CD68-MAC387-cells. Moreover preliminary phenotypic analysis showed that peripheral blood CD14+CD16+ monocytes from uninfected macaques expressed MAC387 and CCR2. We also detected accumulation of MAC387+ cells in brain lesions of HIV-infected patients with dementia. These data suggest that MAC387+ cells detected in brain lesions of SIV-infected CD8+ celldepleted macaques are newly infiltrating monocytes/macrophages that are not cellular reservoirs of SIV-productive replication possibly because of their differentiation stage. However they could serve as potential markers of CNS disease. Whether brain MAC387+ macrophages of SIV-infected CD8+ celldepleted rhesus macaques are derived from blood CD14/CD16 monocyte subpopulations expanded after HIV/SIV infection remains to be determined. This should contribute to decipher the ontogeny of such populations in AIDS-associated neuropathogenesis.
S.51
Effects of minocycline and PMPA on dopamine and dopamine metabolite levels in the caudate nucleus of SIV-infected pigtailed macaques Acquired immunodeficiency syndrome (AIDS) and virus-related neurological disease are significant consequences of human immunodeficiency virus (HIV) infection. Even with the advent of highly active antiretroviral therapy (HAART), the prevalence of HIVassociated neurological disease has increased, as many HAART drugs do not cross the blood-brain barrier.
Minocycline is an off-patent, tetracycline derivative that effectively crosses the blood-brain barrier and has been shown to be neuroprotective in animal models of several neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis. Using our accelerated, consistent model of simian immunodeficiency virus (SIV) infection we showed that minocycline reduces the severity of neurodegenerative indicators such as macrophage activation and infiltration, astrocytosis, levels of betaamyloid precursor protein, and macrophage chemoattractant protein-1 in addition to brain viral loads. Previous studies on post-mortem AIDS patients showed decreased levels of dopamine (DA) in the caudate nucleus (Sardar AM et al 1996), which was also shown to occur in the putamen early in infection in a SIV model (Scheller C et al 2005). Our hypothesis was that minocycline would be able to abrogate the decreases in dopamine levels seen in the brains of SIV-infected macaques. We used high performance liquid chromatography (HPLC) with electrochemical (EC) detection to examine levels of dopamine and its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the caudate nucleus of terminally infected pigtailed macaques that were treated with varying regimens of minocycline with or without PMPA (tanofavir), a nucleotide reverse transcriptase inhibitor. Our data showed that uninfected animals had significantly higher levels of DA in the caudate than terminally infected animals and that this decrease was alleviated with early minocycline treatment or later treatment with minocycline in combination with PMPA. Surprisingly the level of DA in the caudate nucleus of terminally infected macaques did not correspond to severity of CNS lesions or several other markers of neurodegeneration.
S.52
Regulation of CXCR4 expression and impact on HIV-1 infection by the mu-opioid agonist DAMGO in a bone marrow progenitor cell line model Anupam Banerjee, Aikaterini Alexaki, Vanessa Pirrone, Brian Wigdahl, and Michael R Nonnemacher
Drexel University College of Medicine
Several studies now suggest that opioids act as a cofactor in enhancing susceptibility to HIV-1 infection in 8th International Symposium on NeuroVirology Oral Presentations 31 immune cell populations as well as modulating innate, humoral, and cell-mediated immunity. Studies have also shown that under chronic exposure to mu opioid receptor ligands like morphine there is an increased detection in the amount of HIV-1 long terminal repeat (LTR) DNA in cells of the monocyte-macrophage lineage. CD34+/CD38 − progenitor cells within the bone marrow are refractile to HIV-1 infection, probably due to their low level expression of HIV-1 co-receptors, CXCR4 and CCR5. We have previously shown that the human CD34+/CD38+ TF-1 erythromyeloid progenitor cell line can be utilized as a model to study the differentiation process of hematopoietic progenitor cells and how this differentiation process effects the cell surface expression of the HIV-1 receptor and co-receptors and HIV-1 susceptibility. Given these observations, studies have been initiated to identify the presence of the mu opioid receptor on the TF-1 bone marrow progenitor cell line. Studies have also been initiated to determine the functional relevance of this receptor in altering HIV-1 co-receptor expression, susceptibility to HIV-1 infection, impact on HIV-1 LTR activity, and impact on HIV-1 replication during chronic opioid exposure.
S.53
Astrocytic activation causes impaired glutamate clearance and altered CD38/cADPR signaling: Mechanistic links to HIV-1-associated dementia Wei Kou, 1 Sugato Banerjee, 1 Kathleen Borgmann,
Reactive astrogliosis is a key pathological feature of HIV-1-associated dementia (HAD) and is associated with neural injury. However, to date, molecular mechanisms through which astrocyte functions are altered in HAD are incompletely understood. Glutamate is the primary excitatory neurotransmitter in the central nervous system. The regulation of synaptic glutamate concentration by high affinity transporter such as EAAT2 is crucial to avoid excitotoxicity. Astrocytes are known to express EAAT2 that is responsible for over 90% of synaptic glutamate clearance. CD38 is a 45 kD ectoenzyme involved in synthesis and translocation of the potent calcium (Ca2+) mobilizing agents, cyclic adenosine diphosphate-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP+). Recently, the expression of CD38 in astrocytes has been proposed to play a key role in glutamatemediated bi-directional astrocyte-to-neuron communication. Our data suggest that the glutamate clearance capability of astrocytes is impaired in neuroinflammatory disorders such as HAD and the dysregulation of CD38 expression in astrocyte contributes to this impairment. Primary human astrocytes were cultured and treated with pro-inflammatory cytokine IL-1σ or HIV-1gp120, or infected by HIV-1ADA. The glutamate uptake ability of the cells was determined using the Amplex Red Glutamic Acid/Glutamate Oxidase Assay. The astrocyte CD38 and EAAT2 levels were tested by real-time PCR, immunocytochemical and immunohistochemical analyses and confocal microscopy. Our results show that either IL-1σ or HIV1gp120, or HIV-1ADA induced astrocytic activation, and both IL-1σ and HIV-1gp120 significantly upregulated astrocyte CD38 levels. Importantly, our data confirmed that IL-1σ time-dependently downregulated astrocyte glutamate uptake, which was completely reversed by co-incubation with 8-Br-cADPR, a specific cADPR-antagonist. In contrast, 3-Deaza-cADPR, a nonhydrolysable analog of cADPR downregulated astrocyte glutamate uptake in a time-dependent manner. Downregulation of astrocytic EAAT2 expression induced by IL-1σ was also reversed by co-incubation with 8-Br-cADPR. Our data provide new evidence that astrocyte activation is accompanied by impaired glutamate uptake in the context of CD38 dysregulation, thereby contributing to the pathogenesis of neuroinflammatory disorders such as HAD. Our data implicate that the dysregulation of astrocyte CD38/cADPR signaling pathway plays an important role in the maintenance of synaptic glutamate homeostasis. Growing evidence supports an important role for CD8+ T cells in maintaining herpes simplex virus type 1 (HSV-1) in a latent state in sensory neurons. Interferon gamma production by CD8+ T cells blocks HSV-1 reactivation from latency in some, but not in all latently infected neurons. We now demonstrate that the lytic granule components granzyme B (GrB) and perforin (Pfn) are required for a complete block of HSV-1 reactivation from latency in sensory neurons ex vivo.
We also demonstrate that a portion of the HSV-specific CD8+ T cells in latantly infected trigeminal ganglia (TG) express the lytic granule component GrB, can direct lytic granules to the junction with infected fibroblasts, and that lytic granule release leads to activation of the caspase system and morphologic signs of apoptosis in the infected fibroblasts. In contrast, interaction of these same HSV-specific CD8+ T cells with infected neurons, while resulting in directed lytic granule release into the CD8+ T cell/neuron junction, does not lead to activation of the caspase system of the neuron or to morphologic signs of apoptosis. We conclude that CD8+ T cells use lytic granules to block HSV-1 reactivation without destroying latently infected neurons. In contrast, depletion of macrophages in B6 mice markedly decreased their resistance to fatal HSE whereas depletion of neutrophils had no effect on survival, emphasizing the conflicting roles of macrophages and neutrophils in HSV pathogenes in these two strains. Pooled human IgG (IVIG) has become increasingly important both as a replacement therapy for primary and acquired humoral immunodeficiency providing protection against viruses such as hepatitis B, cytomegalovirus, varicella zorster and west nile virus. However, the mechanisms of IVIG protection against virus infection have not been delineated. We report that a single dose of IVIG given at 6-24 h PI protects 100% of 129 mice from fatal HSE. Protection was reduced when IVIG was given later and no protection was seen at 72 h PI. Counterintuitively, survival could not be ascribed to virus neutralization, rather IVIG potently inhibited infiltration of inflammatory monocytes into the brainstem and preserved the integrity of the blood brain barrier relative to untreated infected 129 mice. Results from ongoing studies of the mechanism(s) of IVIG anti-inflammatory effects in HSE will be presented.
S.55
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Immunological synapses in the brain between virally infected astrocytes and CD8+ CTLs mediate profound morphological and functional changes in both T cells and target APCs during the clearance of a brain viral infection Pedro R Lowenstein, 1, 2 Immunological synapses (IS) are microanatomical structures mediate intercellular communication between T cells and APCs. T cell polarization at the IS consists of a peripheral supramolecular activation cluster (pSMAC), which is high in LFA-1, and low in TCR, and a central SMAC, high in TCR, and low in LFA-1. Although studied for many years in vitro, until recently there was no information on their existence in vivo in the context of natural immune responses. We have recently described their existence in vivo during an antiviral immune response in the brain, and are currently exploring their in vivo function. Here we demonstrate that during an anti-viral immune response in the brain and the formation of an immunological synapse, both the T cell and the APC adopt a distinct polarized distribution of membrane protein, cytoskeleton, intracellular organelles and, in the case of the T cell, effector molecules such as IFN-γ . Astrocytes were infected with an adenovirus (Ad) expressing Thymidine Kinase (TK), a marker for the infected cells. 30 days later we induced a systemic immune response against Ads, and 14 days after the immunization animals were sacrificed and brains studied by ICC and confocal microscopy. Brain sections were immunostained for TCR, LFA-1, TK, EAAT2, α-Tubulin, γ -Tubulin, GM130 and IFN-γ . Confocal analysis revealed that target infected astrocytes, normally a multipolar non-polarized cell, became unipolar cells, and thus had undergone profound phenotype changes. In response to the T cell attack astrocytes retracted most cellular processes and retained a single large protrusion towards the T cell. The MTOC and Golgi were also reoriented towards, and into, the protrusion. Confocal analysis also revealed that IFN-γ is polarized in T cells establishing close anatomical contacts with Ad infected cells. IFN-γ polarization was found in cells with or without polarized LFA-1 or TCR. This demonstrates that IFN-γ is selectively polarized towards the APC, and further suggests that maturation of the IS is not necessary for the polarization of IFN-γ . These results demonstrate that CTL signaling, potentially mediated through IS, induces profound morphological and functional changes in both T cells and target infected astrocytes, during a brain antiviral immune response.
HIV enters the CNS early after infection, resulting in cognitive impairment and other neurological manifestations in a large number of individuals. The virus gains access to the CNS, in part, by the transmigration of HIV infected monocytes and perhaps T cells across the BBB. This results in infection of CNS macrophages/microglia and of some astrocytes, as well as in ongoing inflammation. Despite HAART, virus and inflammatory cells persist within the CNS, and the prevalence of the resultant cognitive impairment is increasing. Thus NeuroAIDS is among the most urgents public health concerns worldwide.
Our laboratory demonstrated that the chemokine CCL2 is critical to transmigration of HIV infected cells, and that HV infection of leukocytes results in dysregulation of their surface protein expression, enhancing their passage across the BBB. In addition, this exuberant transmigration of HIV-infected cells results in BBB disruption and activation of CNS cells, as well as in the elaboration of several factors, including HIV tat protein, that cause neuron damage and cell death. Our findings of enhanced HIV-infected cell transmigration, BBB disruption and neuronal damage will be discussed in the context of potential therapeutic intervention.
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Caveolae-associated signaling pathways in HIV-1 tat-induced activation of human brain microvascular endothelial cells Michal Toborek
University of Kentucky Medical Center
Alterations of brain microvasculature and the disruption of the blood-brain barrier (BBB) integrity are commonly associated with HIV-1 infection. These changes are most frequently found in patients with HIV-related encephalitis and in HIV-associated dementia. Our research is based on the hypothesis that impaired function of the brain vasculature can contribute to HIV trafficking into the CNS and the development of neurodegenerative changes associated with HIV infection. Indeed, activation or dysfunction of brain microvascular endothelial cells (BMEC) can lead to the breakdown of the BBB, induction of inflammatory responses and thus provide entry for HIV into the CNS. The leading hypothesis of our research is that the viral gene product, HIV protein Tat, can be responsible for BMEC injury and impaired normal function of the BBB. Tat is released by acutely HIV-1-infected cells and can affect the integrity of the brain endothelium and the BBB by induction of redox-activated signaling. Caveolae serve as the signaling platforms that co-localize various signaling components, including the Ras and Rho signaling cascades. These pathways are critical for the integrity of the BBB, because they regulate the rearrangement of cytoskeleton and permeability of cell junctions. Therefore, the present study was focused on the effects of Tat on the Ras and Rho signaling pathways in human brain microvascular endothelial cells (HBMEC) (Weksler et al., FASEB J 19:1872 FASEB J 19: -4, 2005 . Treatment with Tat markedly activated Ras and RhoA levels in cultured HBMEC. Interestingly, caveolin-1 protein levels were upregulated in parallel to Ras and Rho activation. Silencing caveolin-1 by specific siRNA resulted in diminished activation of Ras but not RhoA in response to Tat. Exposure to Tat also stimulates inflammatory response in BMEC. Therefore, we generated stably transfected cell lines of HBMEC which overexpress peroxisome proliferator-activated receptor (PPAR)-alpha or PPAR-gamma. Overexpression of PPAR-alpha or PPAR-gamma protected against Tatinduced mRNA levels of IL-1beta, TNF-alpha, MCP-1, and E-selectin. The present data indicate the importance of caveolar-mediated signaling in response to Tat exposure and suggest that targeting PPAR signaling may provide a novel therapeutic approach to attenuate Tat-induced dysfunction of brain endothelial cells. Supported by MH63022, MH072567, and NS39254.
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Poor HIV-1 entry via endocytosis but highly productive transcriptional regulation leads to persistent viral replication in astrocytes in vitro Ashok Chauhan, Theophyilus S Vijay Kumar, Suzanne Gartner, and Avindra Nath
Johns Hopkins University
The HIV infection of the central nervous system (CNS) is well documented but least characterized. HIV 8th International Symposium on NeuroVirology
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Oral Presentations infects microglia/macrophages productively, but, infection in astrocytes has been reported to be unproductive. Besides, there are conflicting reports such as no-infection to unproductive viral replication as well sporadic reports on post-entry HIV-replication blocks in astrocytes. We therefore, characterized the HIV infection in astrocytes using sensitive and specific fluorescent reporter assays including GFP-expressing-HIV. Notably, transfection of infectious HIV proviral DNA in astrocytes revealed efficient production of Tat, Rev, Nef and p24. Unambiguously, regulatory proteins Tat and Rev were found to be functionally active in astrocytes. Further, human RNA helicase DDX3 was found to be critical in normal functioning of Rev and its inhibition by antisense-DDX3 impaired the Rev function which subsequently curtailed HIV replication in astrocytes. Despite absence of CD4, CCR5 and LFA-1 (CD11a), DC-SIGN and mannose receptor (MR), however, low-persistent (productive) viral infection occurred in human fetal astrocytes (HFA) and astrocytic cells (SVGA). Intriguingly, endosomal inhibitor Bafilomycin-A enhanced HIV-infection several fold suggesting viral entry via pH dependent endocytosis. To corroborate transfection and wild type HIV infection results, VSV-pseudotyped fluorescent HIV-NL4-3 virus infection in astrocytes revealed productive-noncytolytic infection which developed into persistent state (productive) when serially followed-up for more than 3 months. Similarly, the HIV infection in SVGA and SVGA-reporter cells also developed into chronic state when followed up for more than 6-months. Further, persistently HIV-infected primary astrocytes did not show spread of infection to neighboring astrocytes, albeit, upon co-culture with lymphocytic cells revealed efficient transmission of infection. Our study led to a conjecture that HIV infection in astrocytes is restricted at the viral entry level but still low persistent infection occurs which could serve as a stable reservoir of the HIV in brain.
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Subclinical reactivation and shed of infectious VZV in saliva of astranaunts Randall J Cohrs, 1 VZV enters the nasal/pharyngeal region as an aerosol and replicates in tonsillar T-cells, ultimately resulting in viremia and the development of chickenpox (varicella). After primary infection, VZV becomes latent in cranial nerve ganglia, dorsal root ganglia and autonomic nervous system ganglia along the entire neuraxis. Decades later, a decline in VZV host immunity results in virus reactivation (zoster). An accompanying abstract by Mehta et al. describes the presence of VZV DNA in saliva of zoster patients. Herein, we extend the analysis of salivary VZV from the clinical setting to subclinical reactivation. We studied saliva obtained from three astronauts before, during and after space flight. Quantitative PCR detected VZV DNA in saliva from two of the three astronauts during and shortly after flight in space. No saliva sample was positive for VZV DNA before liftoff. From 2-6 days post flight, early morning saliva samples were also cultured on human fetal lung cells. After one subcultivation, a typical herpesvirus cytopathic effect was seen in samples taken from two of the three astronauts. Immunostaining and PCR revealed that both virus isolates were VZV and not HSV. ORF22-based PCR/sequencing along with FRETbased PCR assays that target specific subgenotype specific SNPs revealed both VZV isolates to be the European strain with an Msp restriction site in ORF62 (107,252 nt). Both of these rare genotypes were different from the only other VZV specimen in the lab at the time (a European strain lacking an Msp restriction site in ORF62 that had been isolated from vesicles of a patient with zoster). These findings extend our previous demonstration of VZV DNA in saliva of astronauts by showing that the virus is infectious. Overall, along with HSV-1 and HSV-2, VZV can reactivate and shed infectious virus in the absence of clinical disease.
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Impaired maturation and function of HTLV-1 specific CTLs in HAM/TSP Mineki Saito, 1 Amir H Sabouri, 2 Shuji Izumo,
